ESR1 and breast neoplasm: These findings suggest that ERα-positive breast tumor cells might exhibit higher sensitivity to specific drugs compared to ERα-negative breast tumor cells, as these drugs induce the degradation of ERα, a transcription factor crucial for the G1 to S phase progression of the cell cycle18.